🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Analysis of DR Progression to Identify Risks and Need for Treatment

Recruitingn/aAges 35 Years - 90 YearsAllAssociation for Innovation and Biomedical Researc…
NCT07417410 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The goal of this observational study is to understand whether vascular and structural changes in the eyes caused by diabetes can help predict which people are more likely to experience worsening diabetic retinopathy (a diabetes-related eye disease) and how these eye changes are related to cardiovascular complications. The study will include about 1,000 people with type 2 diabetes, aged 35 to 90 years, and will take place over twelve months. It may also include a retrospective component, where existing medical and imaging data collected from previous visits (within the last 1 to 5 years) will be analyzed. The main questions it aims to answer are: * Can eye vessel and tissue changes, observed through modern imaging techniques and clinical data, help better describe and predict which cases of diabetic retinopathy will become more severe? * Can these same eye changes help predict the pres

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Diagnosed with type 2 diabetes according to the 1985 WHO criteria. * Age between 35 and 90 years. * Retrospective visit or referenced patients. For the retrospective visit, a documented follow-up of 1-5 years is required, with at least one clinical visit. For the referenced patients, it is required that they have either diabetic retinopathy at the baseline visit, the presence of at least one cardiovascular risk factor at the baseline visit, or cardiovascular complications at the baseline visit. * Signed informed consent. Exclusion Criteria: * Previous laser photocoagulation or intravitreal injections (consider if corticosteroids were administered). * Presence of clinically significant macular edema (CSME) with vision loss or requiring immediate treatment. * Proliferative diabetic retinopathy. * Any ocular surgery within the previous 3 months. * Renal Replacement Therapy (Hemodialysis, Peritoneal Dialysis). * Severe systemic illness, subject to investigator's judgment.
💊

What it tests

  • Not listed
📍

Where

1 site
AIBILI-Clinical Trial Centre
Portugal, Portugal
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy